Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
Research context
Vascular Biogenics Ltd appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Vascular Biogenics Ltd is currently in a long term uptrend where the price is trading 13.4% above its 200 day moving average.
From a valuation standpoint, the stock is 92.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 102.8.
Vascular Biogenics Ltd's total revenue rose by 62.7% to $205K since the same quarter in the previous year.
Its net income has dropped by 26.7% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 96.2% to $-7M since the same quarter in the previous year.
Based on the above factors, Vascular Biogenics Ltd gets an overall score of 3/5.